Uloric Lawsuits For Cardiovascular Deaths, Heart Problems, Strokes
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Uloric (febuxostat), prescribed for the management of chronic gout since 2009, has been associated with increased risk of cardiovascular deaths, heart problems, and strokes. In turn, Uloric lawsuits have been filed against Takeda Pharmaceuticals, the manufacturer of Uloric, alleging this drug company failed to adequately warn doctors and patients about these Uloric side effects.
Drug safety observers, such as the consumer advocacy group Public Citizen, contend that over time there is increasing evidence that the serious cardiovascular side effects of Uloric outweigh any purported clinical benefit from using this particular gout medicine.
Some serious Uloric side effects are:
- Cardiovascular Death (CV Death or CVD)
- Sudden Cardiac Arrest or Sudden Cardiac Death (SCD)
- Heart Failure (HF)
- Heart Attack or Myocardial Infarction (MI)
- Stroke or Cerebrovascular Accident (CVA)
- Unstable Angina with Urgent Coronary Revascularization
In February 2019 the FDA required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, for the Uloric drug label in order to better inform doctors and patients about the increased risks of heart-related deaths as well as deaths from all causes associated with the use of Uloric.
Our law firm is investigating possible Uloric lawsuits where patients have suffered cardiovascular Uloric side effects as personal injury cases or wrongful death claims, depending on the outcome.
We encourage you to submit a Uloric Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Uloric
Based on the results of the CARES study, Health Canada mandated an Uloric label change in early November 2019 which warns about an increased risk of Uloric-related cardiovascular deaths. Uloric is now only approved for use in Canada as a treatment “to lower serum uric acid levels in patients with gout who have an inadequate response or intolerance to allopurinol, or for whom treatment with allopurinol is inappropriate (a second-line therapy).”
To read more of this article, click below:
That information is from this Health Canada document, “ULORIC ® (febuxostat) – Increased Risk of Cardiovascular Fatal Outcomes”, which goes to point out that a higher rate of cardiovascular deaths has been reported in patients with gout who also had cardiovascular disease when treated with Uloric, compared to those treated with the more-established gout drug allopurinol.
This recent drug safety regulatory action by Health Canada is similar to a Drug Safety Update for Uloric issued July 17, 2019 by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
We are investigating Uloric drug injury cases against Takeda Pharmaceuticals America, Inc., which is responsible for Uloric in the US. For additional information, you can see the Uloric Side Effects page on our Drug Injury Law website.[Read article in full at original source]
Earlier articles about Uloric by attorney Tom Lamb on the Side Effects Blog:
- Uloric Warning: Avoid Uloric If Prior Myocardial Infarction, Stroke, Or Unstable Angina
- Uloric Lawsuits Follow Recent FDA Warnings About Heart-Related Deaths And Side Effects
- February 2019: Uloric “Black-Box Warning” For Heart-Related Deaths, Cardiovascular Side Effects
- Uloric Recall Discussed By FDA Advisory Committees In January 2019
- Will FDA Order Uloric Recall Requested In June 2018 By Public Citizen
- Gout Drug Uloric Has Higher Risk Of Death vs. Allopurinol: CARES Trial
- November 2017 FDA Alert: Uloric May Increase Heart-Related Deaths Risk